Equity Profile
Pre-Earnings Brief
Arcus Biosciences is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, its work is crucial as it aims to address significant unmet medical needs in oncology.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
3Q
EPS Beat Rate
88%
Avg EPS Surprise
+28.27%
Avg Stock Reaction
-0.37%
In the last quarter, Arcus reported an EPS of $-0.89, which was better than the expected $-1.11, indicating a positive surprise. However, revenue details were not disclosed, leaving investors eager for more information.
Management Promises & Guidance
Analysts expect a challenging quarter with a consensus EPS of $-0.83 and revenue of $29M. The market is watching closely for any signs of improvement in financial performance.
Bull Case
If Arcus can exceed revenue expectations and show progress in its drug development pipeline, it could lead to a positive market reaction and increased investor confidence.
Bear Case
Conversely, if the company fails to meet earnings expectations or provides disappointing updates on its clinical trials, it could lead to a significant drop in stock price.
EPS
$-0.83Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$29MRevenue figures provide insight into the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will the EPS come in better than the consensus estimate of $-0.83?
A better-than-expected EPS could signal improved operational efficiency and investor confidence.
Q2
What revenue figures will be reported, and how do they compare to the $29M consensus?
Revenue performance is critical for assessing the company's market traction and future growth potential.
Edge
Why consensus could be wrong
The consensus might underestimate the potential for revenue growth driven by recent advancements in Arcus's clinical trials.
Supporting Evidence
The company has a history of beating EPS estimates, with an 88% beat rate over the last eight quarters.
Options pricing suggests a higher expected move than historical averages, indicating potential for significant news.
Recent positive developments in drug trials may not be fully reflected in current revenue expectations.
Key Risk
If revenue comes in above $29M, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether Arcus can sustain investor interest amid ongoing development challenges.
Bull Confirmed If
Reporting an EPS better than $-0.65 and revenue exceeding $55M would confirm the bull case.
Bear Confirmed If
An EPS worse than $-1.01 and revenue below $7M would confirm the bear case.
Pre-Earnings Positioning
Implied Move
±12.2%
Historical Avg
±3.1%
The options market is pricing in a significant potential movement in the stock price, suggesting that investors are anticipating volatility around the earnings announcement.
Options are pricing ±12.2% while RCUS has averaged ±3.1% over the last 8 prints — setup is pricing rich.
30d HV
61.3%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Arcus beats expectations, history suggests the stock could rise by about +0.88%, confirming positive momentum.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity.
Miss
A miss could lead to a decline of around -9.17%, reflecting investor disappointment and potential concerns about the company's trajectory.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOEWS CORP